DK2646040T3 - CARDIOPULMONAL BYPASS PRIMING SOLUTIONS - Google Patents

CARDIOPULMONAL BYPASS PRIMING SOLUTIONS Download PDF

Info

Publication number
DK2646040T3
DK2646040T3 DK11788089.8T DK11788089T DK2646040T3 DK 2646040 T3 DK2646040 T3 DK 2646040T3 DK 11788089 T DK11788089 T DK 11788089T DK 2646040 T3 DK2646040 T3 DK 2646040T3
Authority
DK
Denmark
Prior art keywords
dextran
oncotic
solution
pressure
group
Prior art date
Application number
DK11788089.8T
Other languages
Danish (da)
English (en)
Inventor
Stig Steen
Original Assignee
Xvivo Perfusion Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xvivo Perfusion Ab filed Critical Xvivo Perfusion Ab
Application granted granted Critical
Publication of DK2646040T3 publication Critical patent/DK2646040T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
DK11788089.8T 2010-11-30 2011-11-07 CARDIOPULMONAL BYPASS PRIMING SOLUTIONS DK2646040T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1020300.8A GB201020300D0 (en) 2010-11-30 2010-11-30 Product
PCT/EP2011/069524 WO2012072374A1 (en) 2010-11-30 2011-11-07 Priming solutions for cardiopulmonary bypass

Publications (1)

Publication Number Publication Date
DK2646040T3 true DK2646040T3 (en) 2016-06-13

Family

ID=43500877

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11788089.8T DK2646040T3 (en) 2010-11-30 2011-11-07 CARDIOPULMONAL BYPASS PRIMING SOLUTIONS

Country Status (10)

Country Link
US (1) US8969323B2 (https=)
EP (1) EP2646040B1 (https=)
JP (1) JP6051164B2 (https=)
CN (1) CN103228285B (https=)
DK (1) DK2646040T3 (https=)
ES (1) ES2575206T3 (https=)
GB (1) GB201020300D0 (https=)
PL (1) PL2646040T3 (https=)
RU (1) RU2013127665A (https=)
WO (1) WO2012072374A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3047360C (en) 2017-01-17 2023-09-26 Xvivo Perfusion Ab Organ preservation and/or perfusion solutions
US11707600B2 (en) * 2020-11-18 2023-07-25 CardioDriven, Inc. Level set calibration and assurance for pulmonary artery pressure catheterization
CN117481629B (zh) * 2023-12-29 2024-03-26 成都水木医疗科技有限公司 一种多功能胶体渗透压仪及其测定方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1594697A (en) 1977-04-19 1981-08-05 Pharmacia Ab Oligosaccharide compositions for parenteral use
SE8900586L (sv) 1989-02-21 1990-08-22 Pharmacia Ab Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
US5702880A (en) 1993-06-04 1997-12-30 Biotime, Inc. Blood substitute comprising 0-5 mM K+
SE505499C2 (sv) * 1995-12-15 1997-09-08 Stiftelsen Facthor Förvaringslösning för organ och vävnad eller delar därav från människor och djur innehållande kalcium och nitroglycerin, användning därav samt förfarande för förvaring därmed
US6794124B2 (en) * 1995-12-15 2004-09-21 Stiftelsen Facthor Preservation solution
US5902800A (en) * 1998-03-27 1999-05-11 Glenpharma Dextran formulations and method for treatment of inflammatory joint disorders

Also Published As

Publication number Publication date
ES2575206T3 (es) 2016-06-27
PL2646040T3 (pl) 2017-04-28
JP2013544265A (ja) 2013-12-12
RU2013127665A (ru) 2015-01-10
EP2646040A1 (en) 2013-10-09
CN103228285B (zh) 2016-06-01
US8969323B2 (en) 2015-03-03
CN103228285A (zh) 2013-07-31
JP6051164B2 (ja) 2016-12-27
US20130316977A1 (en) 2013-11-28
GB201020300D0 (en) 2011-01-12
WO2012072374A1 (en) 2012-06-07
EP2646040B1 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
Boer et al. Choice of fluid type: physiological concepts and perioperative indications
Kasper et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses
Niemi et al. Colloid solutions: a clinical update
Vercueil et al. Physiology, pharmacology, and rationale for colloid administration for the maintenance of effective hemodynamic stability in critically ill patients
Base et al. Efficacy and safety of hydroxyethyl starch 6% 130/0.4 in a balanced electrolyte solution (Volulyte) during cardiac surgery
JP5823530B2 (ja) 危険にさらされた組織のオキシジェネーション増進方法
Ismail et al. Principles of intravenous fluids therapy
DK2646040T3 (en) CARDIOPULMONAL BYPASS PRIMING SOLUTIONS
Morgan et al. Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study
Tigchelaar et al. Comparison of three plasma expanders used as priming fluids in cardiopulmonary bypass patients
Böning et al. Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants
Hasija et al. Bivalirudin anticoagulation in neonates and infants undergoing cardiac surgery
Friedman et al. Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients
Kollmar et al. Anesthetic challenges for posterior spine surgery in a patient with left ventricular assist device: a case report
Gertler et al. Cardiopulmonary bypass
Padalino et al. Modified ultrafiltration in pediatric heart surgery
Boldt Fluid choice for resuscitation in trauma
Chan et al. Fluid resuscitation in burns: an update
Krzych et al. Does fluid resuscitation with balanced solutions induce electrolyte and metabolic abnormalities? An in vitro assessment
Mythen et al. Fluid management in gastrointestinal surgery
Wendt‐Hornickle Intravenous Access and Fluid Administration
Li et al. Perioperative fluid therapy: A general overview
Chakraborty et al. A comparison of ringer's lactate with Acetate & maleate containing crystalloid for priming in adult patients undergoing Cardiopulmonary Bypass
Demirtas et al. Retrospective comparison of the effects of centrifugal and roller pump heads on the hemostatic system during open heart surgery
Kapoor 42 Anticoagulation Management during Extracorporeal Membrane